Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa. The heparin-ATIII complex primarily inhibits thrombin and factor Xa, with higher molecular weight heparin more effectively inactivating thrombin.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Prophylaxis and treatment of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE),Treatment of acute coronary syndromes (unstable angina, non-ST-elevation MI),Anticoagulation for atrial fibrillation, cardioversion, and during pregnancy,Anticoagulation in extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass),Off-label: Anticoagulation for acute ischemic stroke in select patients, prevention of left ventricular thrombus post-MI
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
For therapeutic anticoagulation, administer 18 units/kg/hour intravenous infusion after a bolus of 80 units/kg. For prophylactic dosing, 5000 units subcutaneously every 8 to 12 hours.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal half-life: 1-2 hours (dose-dependent: 30-60 min after IV bolus 100 U/kg, up to 2-3 hours with higher doses or continuous infusion). Clearance is biphasic; prolonged in hepatic/renal impairment.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Heparin is metabolized by the liver (heparinase) and to a lesser extent by the reticuloendothelial system. It is also partially depolymerized and desulfated. The clearance is dose-dependent and involves both saturable (cellular uptake and metabolism) and non-saturable (renal excretion) mechanisms. Heparin is partially excreted unchanged in urine.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: 40-60% unchanged via urine (dose-dependent saturable mechanism); hepatic: minimal; fecal: negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Highly bound to antithrombin III (ATIII) and other plasma proteins (e.g., albumin, lipoproteins); non-specific binding ~95% at therapeutic concentrations (saturable).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Vd: 0.05-0.07 L/kg (confined to plasma volume; ~5-7 L in adults). Clinical meaning: low Vd indicates minimal extravascular distribution; primarily intravascular binding to ATIII and endothelial cells.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
SC: 20-30% (dose-dependent, lower with higher doses due to saturable absorption); IV: 100%; not administered orally (negligible absorption).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific GFR-based dose reduction required; heparin is not renally cleared. Monitor a PTT and adjust per protocol.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No Child-Pugh based dosing recommendations; use with caution in severe hepatic impairment due to increased bleeding risk. Monitor a PTT closely.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Loading dose: 75-100 units/kg intravenously over 10 minutes. Maintenance infusion: initial 28 units/kg/hour for infants <1 year, 20 units/kg/hour for children >1 year; adjust to target a PTT.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients may have reduced heparin clearance; lower initial infusion rates (e.g., 15 units/kg/hour) and more frequent a PTT monitoring recommended to avoid over-anticoagulation.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Heparin is not recommended for use as an anticoagulant in patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT). Monitor platelet counts closely. Risk of bleeding, especially in patients with risk factors. Use preservative-free heparin for neonatal patients to avoid benzyl alcohol toxicity.
None.
Risk of heparin-induced thrombocytopenia (HIT) type II, immune-mediated; monitor platelet counts every 2-3 days from day 4 to 14 or until heparin stopped,Risk of bleeding: elderly, renal impairment, concomitant antiplatelet agents,Heparin resistance (antithrombin III deficiency, elevated factor VIII),Hyperkalemia due to aldosterone suppression (risk increased with renal impairment, diabetes, potassium-sparing diuretics),Spinal/epidural hematoma risk with neuraxial anesthesia; monitor for neurological compromise,Do not administer intramuscularly due to risk of hematoma,Use with caution in patients with severe hypertension, recent surgery, gastrointestinal ulcers, or hemorrhagic stroke
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Absolute: History of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) (heparin), known hypersensitivity to heparin or pork products (if porcine-derived), active major bleeding (except when due to disseminated intravascular coagulation), severe uncontrolled bleeding disorders (e.g., hemophilia), suspected intracranial hemorrhage, epidural or spinal puncture within 24 hours (for full-dose anticoagulation),Relative: Severe thrombocytopenia (platelet count <50,000/μL), uncontrolled severe hypertension, recent surgery (especially brain, spinal, or eye), active gastrointestinal ulcer or bleeding, hemorrhagic stroke (acute), pericarditis with effusion, bacterial endocarditis, threatened abortion, severe renal or hepatic impairment, advanced age (>60-70 years)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No direct food interactions. Avoid excessive consumption of vitamin K-rich foods (e.g., leafy greens) if transitioning to warfarin, as it may affect INR.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Heparin does not cross the placenta; no evidence of teratogenicity in any trimester. FDA pregnancy category C (due to risk of maternal hemorrhage).
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Heparin is not excreted into breast milk due to high molecular weight; compatible with breastfeeding. M/P ratio: negligible.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy increases plasma volume and renal clearance; may require higher doses to achieve therapeutic a PTT. Individualize based on a PTT monitoring; subcutaneous doses may need to be increased by 10-20% or more.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
For heparin infusion, monitor a PTT 6 hours after initiation or dose change; goal typically 1.5-2.5 times control. Use weight-based dosing (e.g., 18 units/kg/hr). Avoid intramuscular injections due to hematoma risk. Check platelet counts for heparin-induced thrombocytopenia (HIT) every 2-3 days. Protamine sulfate reverses heparin at a ratio of 1 mg per 100 units.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any unusual bleeding, bruising, or dark stools.,Inform all healthcare providers that you are on heparin.,Use an electric razor and soft toothbrush to avoid injury.,Do not take aspirin or NSAIDs without doctor approval.,Notify your doctor if you experience chest pain, shortness of breath, or leg swelling.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa. The heparin-ATIII complex primarily inhibits thrombin and factor Xa, with higher molecular weight heparin more effectively inactivating thrombin.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% is: For therapeutic anticoagulation, administer 18 units/kg/hour intravenous infusion after a bolus of 80 units/kg. For prophylactic dosing, 5000 units subcutaneously every 8 to 12 hours.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Heparin does not cross the placenta; no evidence of teratogenicity in any trimester. FDA pregnancy category C (due to risk of maternal hemorrhage).. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.